Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

BACKGROUND: The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has been approved for the treatment of metastatic CRC, however tumor response to cetuximab has not been found to be associated with EGF...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Razis, Evangelia, Briasoulis, Evangelos, Vrettou, Eleni, Skarlos, Dimosthenis V, Papamichael, Dimitrios, Kostopoulos, Ioannis, Samantas, Epaminontas, Xanthakis, Ioannis, Bobos, Mattheos, Galanidi, Eleni, Bai, Maria, Gikonti, Ioanna, Koukouma, Alona, Kafiri, Georgia, Papakostas, Pavlos, Kalogeras, Konstantine T, Kosmidis, Paris, Fountzilas, George
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2527615/
https://ncbi.nlm.nih.gov/pubmed/18700047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-234
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares